Crossbow Therapeutics: $77 Million Raised To Advance TCR-Mimetic Antibody Cancer Therapies
By Amit Chowdhry ● Today at 9:25 AM
Crossbow Therapeutics announced it has raised $77 million in a Series B financing to advance the development of its TCR-mimetic antibody therapies designed to treat a broad range of cancers. The funding round was co-led by Taiho Ventures and Arkin Bio Capital, with participation from several new and existing investors, including Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, and Mirae Asset Venture Investment.